Drug discovery with a strong track record

Our core strengths in medicinal chemistry and translational science enable us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is the opportunity to create best-in-class or first-in-class treatments for diseases of unmet medical need. We have built an attractive portfolio of assets and have a strong track record of drug discovery having delivered five molecules to clinical stage development. Our focus is on advancing our differentiated ROCK portfolio which includes our lead asset, RXC007, a next-generation, selective ROCK2 inhibitor for the treatment of interstitial lung diseases and RXC008, a potential first-in-class GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease. Our oncology pipeline is led by RXC004, a Porcupine inhibitor targeting Wnt-ligand dependent tumours, in combination with anti-PD-1 therapy; and our world-class drug discovery engine is advancing a pipeline of research programmes and collaborations in both fibrotic diseases and oncology.